Introduction
The last decade or so has seen major advances in two key areas of biomedicine: new genetic technologies, including genomics, proteomics, transcriptomics, metabolomics and the like; and stem cell technology. Both are touted as offering much promise in terms of our understanding of basic biological process and in the translation of this basic science into mainstream medical practice. But in both areas much further research must be done to realise this promise, and this hinges on the appropriate and adequate supply of essential research tools, particularly human tissue, human cells and human genetic information, which are referred to collectively here as human biological material. Tissue collections, banked cell lines and databases of genetic information, which will be referred to collectively here as human genetic databanks, are vital stores of these research tools. The people who supply the tissue, cells and genetic information to these databanks (collectively referred to here as sources) play a pivotal role in the success of this research endeavour. Hence, its success is, to a large extent, premised on the trust that sources have in it. Increasingly, entire populations of sources are being recruited to provide human genetic material for databanking; in such circumstances, individual source trust becomes synonymous with public trust.
Whilst it is recognised that the issues associated with trust in human genetic databanking are complex and multifaceted, this article focuses on the particular problems associated with trust in the commercialisation of biomedical research utilising human biological materials stored in human genetic databanks. Commercial development of new health care products is a key outcome of the research endeavour. Hence, there is a need for human genetic databanks to have adequate and appropriate intellectual property and access policies that provide some certainty in the rights and obligations of all parties involved. It will be argued that one essential requirement for such policies is that they should explicitly make provision for benefit sharing arrangements from two distinct perspectives: general benefit to society at large; and specific benefit to the sources of the original human biological material and/or their social groupings.
The nature of human genetic databanks
Many human genetic databanks have been in existence for long periods of time, having been established for non-research purposes, for example as stores of pathological samples. 1 Other genetic databanks established for particular research projects also continue to store collections of human biological material. In fact, vast numbers of these collections of biological material are in storage around the world. 2 It has been estimated that 350 million tissue specimens are stored in repositories in the US alone, 3 with a further 20 million added each year. 4 It is now well recognised that these banks of tissue, cells and information can have significant value for research, both now and into the future.
A number of organisations have been established with the specific purpose of coordinating storage and distribution of these stores of biological material. A good example is the American Tissue Type Culture Collection (ATCC), a world-wide repository for biological material, including micro-organisms,
JIBL Vol 03 I 2006
cell lines and recombinant DNA materials. 5 Some of the major research organizations around the world store and make available their tissue via the ATCC. For example, Johns Hopkins University provides its Special Collection of Biological Materials for research purposes via the ATCC catalogue. 6 The Wistar Institute also makes available its Special Collections of various cancer cell lines and hybridomas in this way. 7 In Australia, the Western Australian Research Tissue Network carries out a similar function, providing a facility for banking biological materials in that state. 8 To date, its collections of samples primarily relate to various forms of cancer, including breast, ovarian, prostate, colorectal and gastric. The network also has ethical approval to collect and manage health information related to its collected materials.
The lack of consistency as to methods of collection and storage and access policies has also encouraged the creation of more informal tissue or biospecimen networks, bringing together organisations that have pre-existing tissue collections. The aim of these networks is to standardise policies and procedures for storing and accessing the material rather than to provide actual storage facilities. In Australia and New Zealand, for example, the Australasian Biospecimen Network has been established to provide a forum to address technical, legal and ethical, and managerial issues relevant to human biospecimen repositories within Australia and New Zealand. The Network is a non-profit scientific organisation with voluntary membership. 9 There is also a growing trend to create new largescale population human genetic databanks for use as research tools in wide ranging research projects. 10 In the UK, for example, the Biobank Project aims to collect tissue samples from 500,000 participants aged between 45 and 69 and to use the genetic information extracted from those samples to identify links between genetic and environmental factors in common diseases. It is described as the world's biggest resource for the study of the role of nature and nurture in health and disease. 11 One of the first of the large scale population databanks was established in Iceland, and it has generated a large amount of publicity and academic debate because of the way it is structured, with a distinctly commercial make up. 12 In 1998 legislation was passed for the establishment of a nationwide databank of blood samples and genetic information, which is linked to other health and genealogical information. deCODE Genetics, a for-profit company based in Iceland, has been given an exclusive licence from the Icelandic government to manage the databank. 13 The company is entitled to use the databank for its own research and to on-licence to other researchers.
CARTaGENE is a project based in Quebec in Canada, the aim of which is to recruit 50,000 individuals to provide blood samples and anonymised health information. It will be under the management of a non-profit institute. 14 The Estonian Genome Project Foundation is a hybrid between the Biobank and CARTaGENE models and the DeCode model. The Foundation is a non-profit organisation that has been set up under legislation to manage a national databank of tissue and genetic, health and genealogical information in that country. In addition, a for-profit company, EGeen, has been given the right to sell access and information. 15 Aside from the databanks described above and others of the same nature that store human tissue and frequently combine it with personal genetic and health information, 16 there are also increasing numbers of databases of more generic DNA
sequence information. 17 The most comprehensive and well known is GenBank, the publicly accessible repository of the sequence information produced by the Human Genome Project. 18 Many proprietary databases also exist. For example, Celera Genomics, the company that raced against the Human Genome Project for completion of the human DNA sequence, offered access to its sequence database for a fee. 19 In addition to the Human Genome Project, there are a number of other international collaborative sequencing ventures, notable examples of which are the SNP Consortium and the HapMap Project. Both also make sequence information available in publicly accessible databases. 20 
Ethical considerations
Debate about the appropriate rules for regulating human genetic databanking is intensifying around the world as their number, size and scope increases. Consent by a source to the storage and use of their tissue, cells and genetic information is always likely to be a paramount ethical concern because of the acute privacy and discrimination issues raised by the use of identifiable genetic information. Such matters have been debated extensively in the academic and policy literature, and countries around the world are putting in place procedures to alleviate some of these concerns. For example, the aim of the HapMap project is to map common patterns of human genetic variation and to determine linkages with common diseases like diabetes, cancer and stroke. The early pilot study involved collection of samples from four representative populations in Africa, Japan, China and northern and western Europe, and hence it was highly ethically sensitive. 21 Considerable attention was paid to these ethical sensitivities to ensure that the project had the ongoing support of the populations involved and society as a whole.
There are likely to be ongoing ethical problems relating to the use of materials in databanks that are already in existence, primarily resulting from the inadequacy of consent requirements that were in place at the time that the material was collected. 22 These problems can be alleviated to some extent by ensuring that the material is properly deidentified before it is supplied to researchers. However, it is debatable where any material containing human genetic material can ever be truly de-identified. 23 As there is now better recognition of the importance of securing proper consent to store and use material for research purposes, any research projects using materials from more recently created databanks are likely to pose less problems from this perspective. 24 Nevertheless, the precise nature of the requirement for valid consent to unspecified future research use remains problematic. 25 17 
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Hence, although the contribution that sources make to the research endeavour needs to be better recognised, serious questions have to be asked about the appropriateness of financially rewarding sources for supply of human biological material and also about any further commodification of human genetic databanking and biomedical research. Having said this, there are still good reasons why the involvement of private companies in the development of biomedical technology is justifiable, principally because this is likely to be the only way to bring products to the healthcare market. The whole endeavour of databanking human biological material and utilisation of that material for biomedical research and development is only likely to succeed if these conflicting interests can be accommodated. The word trust perhaps best encapsulates the challenge that lies ahead. Sources of biological material are only likely to be willing to continue to provide their material if they have trust that appropriate ethical safeguards are in place to protect them. But it is increasingly being recognised that source trust goes beyond this. Sources also need to be assured that others are not unduly profiting from their willing participation 35 and that adequate benefit arises out of their participation, whether from their own perspective, or that of the societal group to whom they belong or the public as a whole.
Similarly, it is likely that researchers will only continue to collect, supply, maintain and utilise databanked material if they have trust that they will receive adequate and appropriate benefit, whether this is in the form of broad scientific advancement resulting from the research endeavour, proper acknowledgement of their research input or more overt forms of compensation for their intellectual input. Private companies will only be interested in supporting the endeavour and commercially developing research results if they have trust that these actions are in the best interests of their shareholders. In particular, they will need some assurance that they are able to recover their investment in research and development, which will usually require some guarantee of clean ownership of any intellectual property rights arising out of the endeavour. More generally, and perhaps even most importantly, the broader public will only support human genetic databanking, research and commercial development if they have trust in the whole enterprise, both from the perspective that that an appropriate balance has been achieved between these diverse and potentially conflicting needs to secure benefits in one form or another and also Benefit sharing is being mooted both as an ethically appropriate means of balancing the conflicting interests involved in genetic databanking and also as a potential solution to the problem of loss of public trust.
The problem of loss of public trust
It is probably fair to say that public trust in biomedical science is slowly (or even, in some areas, rapidly) eroding. 37 The last few decades have not only seen the erosion of trust in the profession of medicine, but also in government and science. Well-publicised organ retention scandals in British hospitals have added to this general malaise. The most recent uncovering of fraud by one of the most esteemed teams of stem cell scientists is likely to erode the fragile layer of trust that may have been forming around this technology. The collection of medicinal plants from developing countries for the purpose of drug development has led to widespread use of the phrase biopiracy. When the same methods were use to collect samples of blood and hair from indigenous peoples around the world in the mid-1990s this became known as the Vampire Project. The term helicopter genetics has also been coined to describe the process whereby research teams fly in to a remote location where a particular genetic condition may be prevalent, take family histories, bleed local residents and return to the host laboratory to analyse the samples, never to be seen or heard from again. 38 35 A recent review of public perceptions of genetic databanking found that concerns about commercialisation are prevalent among many publics. 
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The negative impact of such activities on public trust is likely to be most acute where there is commercial involvement. The industry sector probably will always be viewed with some scepticism by the public because of its perceived 'profit at all costs' mentality. The pharmaceutical industry, in particular, is seen as being predominantly profit driven, even though (or perhaps because) it is developing products to serve the public good. The increased commercialisation of human genetic and stem cell research is likely to further threaten public trust in this sector, particularly if there is the perception of conflict of interest, where profits come before patient care or free exchange of research results. 39 Graeme Laurie and Kathryn Hunter argue that represents a break down in the traditional altruistic gift model for organising medical research. 40 It seems that the problem is most acute when the language of ownership is introduced. For example, in 2000 the Australian biotechnology company Autogen Ltd entered into negotiations with the government of Tonga to set up a population database on this small Pacific Island. The project was abandoned in 2002 following public opposition. According to Geneviève Cardinal and Mylène Deschênes, one of the reasons for the failure of the project was concern about 'the conversion of the islanders DNA into corporate property through patent monopolies'. 41 The whole notion that biobanked material can be the subject of commerce, to be bought and sold like any other commodity is deeply troubling for many members of society. 42 Would public trust be restored simply by allowing sources of human genetic material to enter the world of commerce and be paid for their contribution? Is this really what we mean when we talk about benefit sharing? Would it be better to free the research endeavour as far as possible from the fetters of commodification rather than encouraging further proprietary claims? Would it be fair to allow the downstream developers of new healthcare products to reap the benefits of the endeavour, without having to provide a share to other participants? Is benefit sharing the one right answer to this complex web of questions? According to one recent report, the concept of benefit sharing does not attempt to denounce commercialisation, but it seeks to promote the idea that those who directly financially profit ought to contribute to the donors of the material, without such donation amounting to an inducement. 43 Teasing out an appropriate mechanism to achieve this end requires further exploration.
Theoretical rationale for benefit sharing
Both from the ethical analysis outlined above and, a matter of common sense and decency, 44 there are strong grounds for arguing that, at the very least, researchers, databanks operators and other individuals involved in genetic databanking have the following moral obligations:
-to sources, to properly recognise their willing participation; -to vulnerable members of society, to avoid coercion; -to the scientific community as a whole, to disclose and make available the results of research using databanked materials; and -to society as a whole, to ensure that the benefits stemming from research using databanked materials are shared by all, with particular focus on the needs of disadvantaged groups in both developing and developed countries.
Do any of these obligations equate with a moral obligation to share in the financial rewards derived from research and development utilising databanked human genetic material? Ruth Chadwick and Kàre Berg express the view that although intuitively, sharing of economic benefits seems morally desirable, it is also difficult to identify any specific reason why the pharmaceutical industry should be obliged to share the revenue from their genomic research. 45 Others have also commented on the difficulty in finding some underlying normative justification for benefit sharing. 48 According to Richard Gold and Tim Caulfield, these problems arise because the focus of the analysis remains based in property rhetoric and the obligation to compensate for contribution. 49 In the alternative, they support justifications based on distributive justice, that everyone has the right to share in scientific advances and their benefits. 50 Berg uses the language of solidarity, which extends from a responsibility to make one's biological material available for research to support for people in need to a duty to help the needy or to help countries develop. 51 Some policy documents also provide support for the applicability of both of these principles when attempting to find justifications for benefit sharing, adding further that recognition that the human genome is the common heritage of humanity 52 requires that benefits accruing from genetic research should benefit all the people. 53
These principles provide solid justification for sharing of benefits across society, but they do not provide a great deal of support for arguments that individual sources or the groups to whom they belong deserve to receive special benefits. In addressing this problem, Charles Wiejer argues that what really is required is a new ethical principle, the principle of respect for communities. 54 But whether benefit sharing actually needs some form of normative ethical justification is a moot point. Laurie and Hunter sensibly bring the debate squarely back to the issue of trust. 55 They argue that, aside from these normative principles, lack of trust of itself is sufficient rationale for benefit sharing. In support of this argument, they suggest that benefit sharing: 'allows the normatively appealing gift model while redressing the palpable imbalance of power in the researcher-subject relationship' by providing a 'continuing obligation to ensure that financial benefit (profit) to the researcher is shared in some way with the participant or her community' [their emphasis]. 56 Accepting that there is a strong linkage between trust and benefit sharing, and that some form of benefit sharing is desirable both practically, to promote trust, and also (perhaps more arguably) from the normative perspective, the difficult issues of determining what benefits should be shared and how they should be allocated remain. Mark Rothstein notes that calls for benefit sharing arose in the first place because of actual or perceived exploitative behaviour. 57 Clearly, this problem needs to be addressed. However, he also expresses concern about what he refers to as 'true benefit sharing', which, he says, would require a restructuring of the biomedical research system, technology transfer laws, and intellectual property laws. 58 Kàre Berg also raises a number of practical difficulties with sharing of financial benefits. In particular, he cautions against creating a general rule that financial compensation should be paid at the outset because of the difficultly in predicting success and the stultifying effect that this could have on university research. 59 The benefit sharing obligation does not necessarily have to be restricted in this way, to focus exclusive- 60 It is argued here that if benefit sharing is a desirable end in this area of human genetic databanks then it must be addressed in a genuine way. If researchers and databank operators try to satisfy obligations to provide for benefit sharing by means of trite statements of future possibilities, then rather than promoting trust, they could further erode it. This is not to say that the only benefit that should be considered is financial benefit.
Emerging international principles
A number of international principles provide some guidance in clarifying the concept of benefit sharing and the obligations that it might entail in the area of human genetic databanking. 61 Some guidance can be obtained from the Convention on Biological Diversity (the CBD) and associated guidelines in relation to access to non-human genetic resources. 62 Article 15.7 of the CBD calls for fair and equitable sharing of the results of research and development and the benefits arising from the commercial and other utilization of genetic resources. It is important to note that the CBD and associated guidelines only apply to non-human genetic resources. However, it has been argued that they, nevertheless, provide a rational starting point in determining how benefit sharing could apply in the context of human genetic material. 63 The International Treaty on Plant Genetic Resources for Food and Agriculture, adopted by the Food and Agriculture Organisation in November 2001, also has similar provisions. The Treaty's objectives are the conservation and sustainable use of plant genetic resources for food and agriculture and the fair and equitable sharing of benefits derived from their use, in harmony with the CBD, for sustainable agriculture and food security.
Although the benefit sharing provisions in these instruments have caused concern in some quarters, they do make good common sense. Kàre Berg has commented that there would be an almost universal feeling that it would be unfair to take natural resources to make marketable products without giving something back. 64 He argues that the same is true where research on genes in a family leads to marketable products and revenues for the pharmaceutical industry and the family is given nothing back. 65 Yet there is much less support in international law for benefit sharing in respect of human genetic material.
UNESCO's International Declaration on Human Genetic
Data 66 is perhaps the most influential normative statement on benefit sharing in relation to biomedical research. It provides that:
benefits resulting from the use of human genetic data, human proteomic data or biological samples collected for medical and scientific research should be shared with the society as a whole and the international community. 67 Notably, it adds that special assistance may be provided to the persons and groups that have taken part in the research. 68 The Declaration goes on to provide some further clarification of the forms that benefit sharing may take, 69 but does not provide any further specific guidance as to the nature of the special assistance mentioned above. UNESCO's earlier Universal Declaration on the Human Genome and Human Rights also emphasises the importance of international collaboration and free exchange of knowledge, 70 but is silent on benefit sharing as such. 
Ibid Article 19(a)(i). 69 Ibid Article 19(a)(ii)-(vii).
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more explicit guidance on the appropriateness of benefit sharing and the obligations it entails, both from the broad societal perspective and the more specific perspective of the source and/or their social group. 71 The statement recommends that:
-all humanity should share in, and have access to, the benefits of genetic research; -benefits should not be limited to those individuals who participated in such research; -there should be prior discussion with groups or communities on the issue of benefit-sharing; -even in the absence of profits, immediate health benefits as determined by community needs could be provided; -at a minimum, all research participants should receive information about general research outcomes and an indication of appreciation; and -profit-making entities should dedicate a percentage (e.g. 1% -3%) of their annual net profit to healthcare infrastructure and/or to humanitarian efforts.
The first five dot points encapsulate some of the key concerns that have been raised earlier in this article. The last dot point is more controversial. It clearly puts the issue of financial benefit sharing onto the agenda, and it avoids the problem of coercion by recommending that profits should be dedicated to healthcare infrastructure or other humanitarian needs. However, on the one hand, this may not provide adequate specific benefit to the source or to their social group and on the other hand, the obligation to provide a fixed percentage irrespective of the actual success of the product may be seen as too significant an impost for some commercial entities.
The Statement does provide some further clarification that benefit means more than financial benefit. It defines benefit as:
a good that contributes to the well-being of an individual and/or a given community (e.g. by region, tribe, disease-group...). Benefits transcend avoidance of harm (non-maleficence) in so far as they promote the welfare of an individual and/or of a community. Thus, a benefit is not identical with profit in the monetary or economic sense. Determining a benefit depends on needs, values, priorities and cultural expectations.
There is support in the academic literature for including in this broad definition of benefit sharing such scientific benefits as: prompt diffusion of research results, collaboration with members of the scientific community and attribution of licences for patented inventions; and such general and specific social benefits as: access to future treatments resulting from the research, donation of part of the profits to a local humanitarian organisation and financial support for research or contribution to health technology infrastructures. 72 There are some international instruments that provide further specific guidance on benefit sharing in relation to human genetic databanking. As with the more generalist instruments, there are two aspects that need to be balanced. One aspect focuses on the need to share benefits amongst the community as a whole, rather than at the level of the particular individual or the group. Indeed, there is a growing trend to describe databanks as global public goods rather than as collections of individual pieces of property. 73 UNESCO's Statement on Human Genomic Databases describes databanks in this way, and in recommendation 3 it states that the free flow of data and the fair and equitable distribution of benefits from research using databases should be encouraged. At the same time, Recommendation 6 recognises that researchers, institutions and commercial entities have a right to a fair return for their intellectual and financial contributions.
There is also some support at the international level for the more specific aspect of benefit sharing at the level of the individual or group. The World Health Organisation (WHO), for example, emphasises that, in recognising the potential value of human material and human genetic information, it is also necessary to recognise the inherent value of the person from whom the material or information is derived. 74 Hence, it suggests that, in exchange for the supply of materials, there should be an undertaking that some kind of benefit will ultimately be returned, either to the individual from whom the material is taken or the general class of people to whom the individual belongs. The stated rationale for this conclusion is that intellectual property 
rights in the products of research do not 'accord an unfettered reign to the rights holder to do what they wish with the property', but rather an obligation to seek a more equitable equilibrium in the relative weighting of interests. 75 In summary, these instruments provide support for both general and specific benefit sharing. They also provide some clarification as the nature of the benefit sharing obligation. It seems that it is difficult to divorce benefit sharing entirely from the financial realm. Having said this, there is more to it than a simple requirement to return a fixed percentage of profits. Clearly then, the actual content of the obligation still needs further elucidation. It is equally necessary to move beyond the principles and consider how the obligation actually arises and can be enforced in practice.
Existing domestic ethical and legal benefit sharing obligations
Although the number of international instruments that raise the issue of benefit sharing is growing, the same cannot be said domestically, at least in the industrialised countries that are actively promoting the development of a medical biotechnology industry. 76 In many of these countries, ethical guidelines provide no absolute obligation to inform research participants about the acquisition of intellectual property rights or about arrangements for commercial development of research findings. 77 Even more clearly, there is no obligation to return any of the profits of commercialisation to participants, because of the widely held view that offering financial inducement for participation in research is unethical. 78 A number of policy documents from around the world that have focused specifically on the appropriate regulation of human genetic databanks have consistently recommended that sources should not receive financial reward for providing their material for databanking and that they should be informed of this when asked for their consent. 79 They do, at least, recommend that when sources are asked to consent to collection storage and utilisation of their material they should be informed of any commercial objectives or likely outcomes of research using their material as part of the process of obtaining fully informed consent. 80 But they provide little guidance as to whether or not there are any benefit sharing obligations and, if such obligations do arise, what their content might be. Similarly, although a number of domestic laws impose rights and duties in relation to the commercialisation of the results of databank research, none of these provides a great deal of assistance in determining whether there are any legally enforceable benefit sharing obligations. 81 For example, patent law provides for temporary monopolies for inventions that satisfy the requirements of novelty, inventive step and industrial applicability and that are fully disclosed. Cell lines and genes are considered to be capable of fulfilling these requirements in many jurisdictions, provided that they are in some way isolated from their natural environment. 82 Patents are made available to inventors, which might include the researchers who carry out projects using banked materials and perhaps the bankers themselves. However, there is no room in this definition to include the sources of the raw materials from which inventions are derived. Moreover, there is no requirement in patent law to inquire into the ethical appropriateness of research that leads to patentable inventions. The international Agreement on Trade-related Aspects of Intellectual Property lists the matters that members of the World Trade Organisation are allowed to exclude in their domestic patent legislation. The only exclusion that may be relevant is for inventions, the commercial exploitation of which would be contrary to pubic order or morality. 83 It is difficult to see how this exclusion would allow for inquiry into the research that precedes the invention. The law on ownership of human tissue and human genetic information is less emphatic on the absence of benefit sharing obligations, but nevertheless appears to be similarly unhelpful. The widely accepted position is that both unprocessed human tissue and the human genome itself are not generally capable of ownership and there is little or no authority for a successful claim by a source to legal ownership (or interest) in any commercial product derived from their tissue. 84 The commercial product is generally seen as severed where there is an intervening and independent creative dealing with the material. However, from time to time there have been calls for recognition of sources' property rights in their biological materials. It is argued that this would facilitate ongoing control by sources of the material they provide and give them an entitlement to share in the profits arising out of commercial use of their material. 85 In effect, sources would be provided with inalienable property rights that cannot be waived or assigned to the director of the repository or other interested parties. 86 However, this concept of inalienability has been criticised because, although it would provide for ongoing control, it would inhibit profit sharing and could actually add confusion to the legal status of human biological material, rather than clarify it. 87 It is salutary to note that in Australia, a comprehensive report by the Australian Law Reform Commission and Australian Health Ethics Committee on the protection of genetic information recommended against the recognition of property rights in human biological material for various reasons. 88 Equity may intervene if there is breach of a fiduciary obligation, for example. 89 However, even if a researcher or a databank manager were found to owe a fiduciary obligation to sources of biological material, it is most unlikely that such an obligation would extend to the downstream developers of commercial products, even if development of the products was directly linked to that particular material. Contract law could also have a role to play, particularly where benefit sharing arrangements have been specifically negotiated and agreed to. 90 However, absent a legally enforceable contract with express benefit sharing terms, it is unlikely that contract law could provide much assistance. Even if the normal consent arrangement between the source of human biological material and the researcher or databank manager could be seen as contractual in nature, it is unlikely that benefit sharing terms would be implied. In any case, concern has been expressed about the propriety of using contract law to solve such future ethical dilemmas. 91 In summary, then, there is a lack of certainty in the extent to which relevant domestic laws could be used to impose benefit sharing obligations on databank managers, researchers and downstream users without more precision as to the nature of obligations. Despite the absence of clear legal obligations or ethical guidelines, it is argued here that the funding agencies, databank operators and researchers themselves have an ethical obligation to set their own standards providing for benefit sharing, with the assistance of adequate and appropriate policy documents. It is also sensible from the practical point of view to do so, to promote trust in their endeavours.
Human genetic databank policies
As the number and diversity of databanks burgeons, so too does the number and diversity of databank policies. Whilst consolidated facilities like the ATCC and the more informal networks are providing a greater degree of uniformity in these policies, a number of databanks still either lack formal policies or do not make their policies readily available. In this section, the key features of some of these policies are discussed, particularly as they relate to access, intellectual property and benefit sharing. A study commissioned by the National Cancer Institute National Dialogue on Cancer provides an insight into how intellectual property and access issues are dealt with in human genetic databanks The purpose of the study was to assess the usefulness of these repositories in genomics-and proteomics-based cancer research and to identify 'best practice'. 92 The final report discusses best practice in a range of areas, including privacy, ethics and law as well as public relations and marketing. For the present purposes, Chapter 8 on Intellectual Property and Legal Issues is the most relevant.
The report gives an indication of the core features that should be included in arrangements for access to deposited materials, which include the following:
-use should only be for the purpose specified in the application for access; -no attempt should be made to obtain identifying information; -there should be no transfer to third parties without prior written permission of the repository; and -any publication resulting from use of the materials should acknowledge the repository.
These requirements are likely to fulfil the obligation to provide a basic level of protection to sources of deposited material. However, disappointingly, there is nothing in these requirements that specifies that the contribution of the source should be recognised in any way.
Despite a finding that it is best practice to have an intellectual property policy, not all of the repositories surveyed actually had one. 93 Nevertheless, some general trends regarding handling of intellectual property issues do emerge from the survey. It was found that most repositories do not retain any rights to downstream intellectual property produced using the material they distribute, unless they are undertaking collaborative research, in which case the intellectual property may be jointly owned. 94 As a general rule, the institution or organisation where the research is conducted claims ownership of the intellectual property rights.
The National Cancer Institute report further concludes that it is also best practice to require a material transfer agreement (MTA) to be executed in accordance with the same terms as the best practice intellectual property policy. This is important, because it gives contractual force to the terms of the intellectual property policy included in the MTA. However, the report provides no evidence of the inclusion of any benefit sharing obligations in the intellectual property policies or MTAs. Although it is generally specified that individuals who contribute material have the right of withdrawal unless stripped of identifiers, they generally have no other rights, including no right to compensation for their participation.
The UK Biobank draft Policy on Intellectual Property and Access is cast in somewhat similar terms. 95 It has the usual provision that intellectual property arising out of research using the resource vests in the investigator creating it. However, its access policy is somewhat unusual in that it provides that, as a general rule, researchers will not be provided with access to stored tissue. Instead, analysis will be undertaken by Biobank or a laboratory contracted by it. An access agreement has to be entered into, and an access fee has to be paid, although fees for non-commercial research are nominal. Where tissue is provided, a standard form MTA is required to be executed.
The standard ATCC MTA 96 provides the signatory with permission to make and use material, replicates and derivatives for research purposes in the signatory's own laboratory only. No permission is given to distribute, sell or otherwise transfer the provided material or replicates or derivatives. Commercial use is prohibited without authorisation. ATCC and/or its contributors retain ownership of the material, replicates and derivatives (but presumably not the intellectual property that is created from their use).
Organisations that make their collections available through the ATCC may require a separate MTA to be These MTAs and intellectual property policies allow databank operators to retain some control over the material that they provide access to. Restrictions on transfer to third parties are particularly important in deterring inappropriate use of accessed material. In some circumstances, the databank operators will be able to claim a share of intellectual property generated through use of the material. Whilst disputes about contribution and ownership will inevitably arise, it is probably fair to say that, as a general rule, where intellectual property and access policies of this nature are in place they are likely to provide an acceptable level of clarity to promote trust by the relevant parties (databank operators, researchers and commercial developers). However, there is a marked absence of any requirement whatsoever to provide for any other form of benefit sharing, whether in the broad sense of sharing with society or in the specific sense of sharing with the source and/or their social group.
The operators of databases of human genetic information tend to be more explicit in providing for broad social benefits. The primary way that this form of benefit sharing is secured is by making the data available rapidly and without restriction. For example, the entirety of information relating to the HapMap Project is in the public domain. In the early stage of the project it was felt necessary to impose restrictions on the use of data. In order to register for access to the online database participants were required to accept the terms of the licence on the click of a button. 98 Without going into details about the scientific rationale for this, it was felt necessary because it was possible for users to capture early stage data and take out patents, thereby potentially restricting access for other users. The licence required users to undertake that they would not restrict others from accessing or using the data produced by the project. This obligation was no longer required once further data had been placed in the public domain, which occurred about 15 months into the project.
In addition to the scientific benefits likely to arise out of rapid release of information, participants in the HapMap Project claim that it offers the following benefits to society:
it is hoped that the HapMap Project will eventually benefit the health of all people. Most of the benefits, however, will not be immediately apparent, and some might take years to materialize. So, in the short term, the main beneficiaries will not be sample donors, their families or their communities, but researchers, who will gain professional rewards, and companies, that will be able to develop drugs, diagnostic tests or other commercial products from research using the HapMap. 99 Commentators like Laurie and Hunter would doubtless object to this statement on the basis that the benefit is too abstract in nature, and does not adequately recognise the input of sources of the original material. However, in circumstances such as this, where the material that is being provided by the databank is DNA sequence information that is essentially generic and where there are likely to be many steps between the original sequencing and
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product development, the benefit of free exchange of information together with a general promise of future benefit is probably sufficient. But the situation is quite different for the UK Biobank and like projects, where each individual source is expected to make their tissue available for research via the databank, together with other information. In such circumstances serious questions have to be asked as to whether research and the mere promise of future healthcare benefits is sufficient. Yet this is precisely what the UK Biobank intellectual property and access policy offers in its core principles of intellectual property and access. 100 The policy goes even further than this, expressly providing that, a general rule, there is no requirement to return a share of any profits generated using the Biobank resource to Biobank. 101 There is very little evidence of any explicit requirement for specific benefit sharing with sources or their social groups in the vast majority of databanking policies throughout the world. On the contrary, some policies take great care to ensure that sources know they are not entitled to any financial benefit from their contribution to the research effort but are curiously silent on other forms of benefit. One such example is the Biorepository Protocols of the Australasian Biospecimen Network, which simply state in the section of the Protocols dealing with ethical issues associated with use of human biospecimens (or human biological material, using the terminology used elsewhere in this article) that the following information should be provided to sources on commercial issues:
Our research is mostly directed to improving understanding of disease. Sometimes the research will lead to findings that result in the development of a commercial test or treatment that may be overseen by pharmaceutical companies. Australian law indicates that there is no financial reward or payment to you in such an event. 102 There is no mention in the guidelines of any requirement to explain whether any financial or other benefit accrues to the biorepository as a result of the development of a commercial test or treatment, or whether there is any other form of benefit to the source, or any broader public benefit.
In contrast, the Quebec Network of Applied Genetic Medicine is much more explicit on the need to provide for benefit sharing arrangements in its pro- This clause goes on to address the need for freedom of research, which it says should be promoted by respecting the principle of public access and management of the potential for conflict of interest to arise from the commercialisation process. As with the HUGO Statement, this clause encapsulates many of the key concerns highlighted earlier and it could provide a model for other databanking policy statements. Admittedly, the policy is cast in fairly broad terms and does not provide specific details as to how benefit sharing should actually be provided for. 104 But this may well turn out to be the most sensible option. It has been recognised elsewhere that a 'one size fits all' model is not appropriate and that benefit sharing policies can only provide general guidance. 105 By inviting discussions about benefit sharing at the outset, the policy encourages the parties to consider the social group's particular needs and cultural values.
A report by the Newfoundland and Labrador Department of Health and Community Services raises similar considerations, but recommends that the province should play a central role in negotiating benefit sharing arrangements, which, it further recommends, should be required for any human genetic research with commercial potential. 106 These arrangements might include free access to genetic tests for all residents of the province, for example. 107 Some of the reasons put forward to justify the proposal are: that health care is a common good and a community held responsi- 
bility; that residents of Newfoundland and Labrador collectively share the burdens and benefits of individual genetic predispositions; and that human DNA is a communal resource. 108 Whilst arrangements of this nature may be difficult to implement for the larger scale databanking project, they do present an interesting way of setting up the administrative framework for negotiating and enforcing benefit sharing obligations. It is likely that various other models of benefit sharing frameworks will emerge once the need to address this issue is more widely recognised.
Conclusion
There appears to be a growing realisation that research using databanked materials will be facilitated by clear intellectual property and access guidelines. However, the same cannot be said with regard to benefit sharing. There is scant evidence that this important issue is being taken seriously. Bartha Knoppers and Lori Sheremeta have suggested that it is time to go beyond the rhetoric of benefit sharing and implement practical benefit sharing measures. 109 However, there is an even greater difficulty -for the most part, the people providing the rhetoric are not those who are most directly involved in databanking. Until policy makers, operators, researchers and commercial developers become engaged in discussions about benefit sharing, the rhetoric is empty. The theorists have presented convincing arguments as to why both general and specific benefit sharing are desirable ends, particularly from the perspective of maintaining trust. Now is the time for all parties engaged in databanking to seriously consider how to implement appropriate benefit sharing mechanisms. They should not see benefit sharing as a threat to the commercial success of the endeavour but as an important component in its success. As Sheremeta has put it:
… benefit sharing should be considered as a mechanism (or rather a spectrum of mechanisms) to balance the commercial interests with those of research participants in a way that is both respectful and reflective of the relative contributions to the research endeavour. 110 It is also important to recognise that benefit sharing does not equate with paying research participants for their involvement. Nor does it equate with commodification of human tissue. But it does recognise the important contribution that participants, their social groupings and the public at large make to the research endeavour. For this reason, benefit sharing should be a mandatory consideration in human genetic databanking. Provided that all players in the databanking arena are involved in formulating best practice guidelines for benefit sharing policies and that benefit sharing arrangements are handled with sensitivity and transparency, there can be little doubt that public trust in the endeavour will be enhanced.
